Clinical Trials Directory

Trials / Completed

CompletedNCT01525043

Study to Evaluate the Efficacy of the Synera Patch Compared to Naproxen Sodium for Epicondylitis of the Elbow

Randomized, Parallel-Group, Open Label, Dose Finding Study to Evaluate the Efficacy of Synera Patch Compared to Naproxen Sodium for the Treatment of Lateral and Medial Epicondylitis of the Elbow

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
78 (actual)
Sponsor
International Clinical Research Institute · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Accepted

Summary

The purpose of the this study is to evaluate the sfaety and efficacy of Synera(R)for patients with lateral and medial epicondylitis and compare it to Naproxen sodius.

Detailed description

The objective of this single center is to evaluate the safety and efficacy of Synera ® in lateral and medial epicondylitis . This is an open-label, comaparative study study where the subjects will be randomized to one of the following groups: 1. Synera patch ®: A single patch applied for 4 hours twice daily approximatey 12 hrs apart to the medial or lateral side of the index elbow 2. Synera patch ®: A single patch applied for 12 hours/day to the medial or lateral side of the index elbow 3. Naproxen Sodium: 500mg bid

Conditions

Interventions

TypeNameDescription
DRUGNaproxenNaproxen 500mg BID for the first 2 weeks
DRUGSynera patch twice daily1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks
DRUGSynera patch for 12hrs/day1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
DRUGNaproxen500mg bid
DRUGSyneraTopical appication of single patch to elbow for 12hrs/day
DRUGSyneraSingle patch applied to elbow for 4hrs/twice daily

Timeline

Start date
2012-02-01
Primary completion
2013-02-01
Completion
2013-09-01
First posted
2012-02-02
Last updated
2014-03-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01525043. Inclusion in this directory is not an endorsement.